Analysis of the launch time and sales situation of mobosetinib/mobosetinib in China

Mobocertinib is an innovative targeted drug targeting non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Its launch time and sales in the Chinese market have attracted much attention from patients. In 2023, mobosetinib was officially approved by the China National Medical Products Administration (NMPA) for the treatment of patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum-containing chemotherapy. This approval marks an important progress in the treatment of lung cancer in China and provides a new treatment option for patients with EGFR exon 20 insertion mutations.

The sales of mobosetinib in China are mainly through large hospitals and designated pharmacies. Patients need to purchase it with a doctor's prescription and undergo genetic testing to confirm the presence of EGFR exon 20 insertion mutations. At present, the price of moboxetinib is relatively high, but some patients can reduce their financial burden through medical insurance reimbursement or assistance programs from pharmaceutical companies. For example, some charities work with pharmaceutical companies to provide drug assistance or cost reductions to eligible patients, helping more patients gain access to treatment.

In addition, the launch of mobosetinib has also promoted the development of precision treatment of lung cancer in China. EGFR exon 20 insertion mutation is a relatively rare type of mutation, for which traditional chemotherapy and first- and second-generation EGFR-TKI have limited efficacy. Mobosetinib significantly extends the progression-free survival (PFS) and overall survival (OS) of patients by specifically inhibiting the EGFR exon 20 insertion mutant protein, bringing new hope to these patients.

In general, the launch of mobosetinib in China provides an important treatment option for patients with lung cancer with EGFR exon 20 insertion mutations. Despite the higher price, more patients are expected to have access to this innovative drug through health insurance reimbursement and assistance programs. With the continuous development of precision medicine, the application prospects of mobosetinib will be broader and bring more survival benefits to lung cancer patients.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib